Esperion (NASDAQ: ESPR), makers of NEXLETOL and NEXLIZET is on a
mission to educate patients on the cardiovascular risks of
uncontrolled or under controlled LDL cholesterol, an asymptomatic
disease that “lurks” inside artery walls.
“The Lipid Lurkers campaign was developed as a visual way to
bring high LDL cholesterol to life and help patients understand and
become better educated on the havoc that too much bad cholesterol
is causing inside their artery walls,” according to Eric Warren,
R.Ph., Chief Commercial Officer, Esperion. “Of the multiple
concepts tested, the Lipid Lurkers campaign was rated best among
patients with high LDL-C on three key attributes: stopping power,
impact, and motivation to ask their doctor about NEXLETOL and
NEXLIZET.”
Recently, the FDA approved a broad label expansion for NEXLETOL
and NEXLIZET making the medications the only non-statins indicated
to reduce cardiovascular events for primary prevention patients.
This expands the treatable populations for the medications to more
than 70 million in the U.S. The label expansion was approved based
on data from the positive CLEAR Outcomes study, which reflects a
highly differentiated product profile.
Digital Strategy to Target Key Audiences
“Our target audience in the U.S. are adults who have been
diagnosed with high LDL-C who cannot take statins, cannot optimize
their statin, or their statin dose is optimized, but they are not
at the LDL-C level that their HCP desires,” Warren noted. “With our
expanded label, we have broadened our focus to not only include
patients who had have already had a cardiovascular event, but now
also those who are at risk of their first event.”
Esperion has adopted a “digital first” strategy enabling the
company to gain the reach and frequency to generate increased
awareness among the target audience. Digital channels, including
search, direct, lifestyle, and programmatic display, social
(Facebook and Instagram), and emails also allow the marketers to
effectively measure what’s working and where to optimize to achieve
better growth within the key target audience. The Lipid Lurker
characters will also be featured in point of care materials in HCP
offices including waiting room videos and patient brochures.The
campaign launched in April and initial results show that the
campaign is reaching its target audience and having an impact. For
the month of May 2024, the site recorded 190,000 clicks for more
information generated from the campaign tactics.
“The Lipid Lurker campaign aims to demonstrate that patients can
empower themselves to ‘Take Control of Their Lipid Lurkers’,”
Warren said. “This message is underscored by the graphic of the
patient throwing the Lipid Lurkers in the trash.”
The Esperion marketing team works with GSW, Powered by Syneos
Health. The design for the Lipid Lurker characters was created by
GSW.
To see the Lipid Lurkers in action, go to nexletol.com.
INDICATION NEXLIZET and NEXLETOL are
indicated:
- The bempedoic acid component of NEXLIZET and NEXLETOL is
indicated to reduce the risk of myocardial infarction and coronary
revascularization in adults who are unable to take recommended
statin therapy (including those not taking a statin) with:
- established cardiovascular disease (CVD), or
- at high risk for a CVD event but without established CVD.
- As an adjunct to diet:
- NEXLIZET, alone or in combination with other LDL-C lowering
therapies, to reduce LDL-C in adults with primary hyperlipidemia,
including HeFH.
- NEXLETOL, in combination with other LDL-C lowering therapies,
or alone when concomitant LDL-C lowering therapy is not possible,
to reduce LDL-C in adults with primary hyperlipidemia, including
HeFH.
IMPORTANT SAFETY INFORMATIONNEXLIZET and
NEXLETOL are contraindicated in patients with a prior
hypersensitivity to bempedoic acid or ezetimibe or any of the
excipients. Serious hypersensitivity reactions including
anaphylaxis, angioedema, rash, and urticaria have been
reported.
Hyperuricemia: Bempedoic acid, a component of NEXLIZET and
NEXLETOL, may increase blood uric acid levels, which may lead to
gout. Hyperuricemia may occur early in treatment and persist
throughout treatment, returning to baseline following
discontinuation of treatment. Assess uric acid levels periodically
as clinically indicated. Monitor for signs and symptoms of
hyperuricemia, and initiate treatment with urate-lowering drugs as
appropriate.
Tendon Rupture: Bempedoic acid, a component of NEXLIZET and
NEXLETOL, is associated with an increased risk of tendon rupture or
injury. Tendon rupture may occur more frequently in patients over
60 years of age, in those taking corticosteroid or fluoroquinolone
drugs, in patients with renal failure, and in patients with
previous tendon disorders. Discontinue NEXLIZET or NEXLETOL at the
first sign of tendon rupture. Consider alternative therapy in
patients who have a history of tendon disorders or tendon
rupture.
The most common adverse reactions in the primary hyperlipidemia
trials of bempedoic acid, a component of NEXLIZET and NEXLETOL, in
≥2% of patients and greater than placebo were upper respiratory
tract infection, muscle spasms, hyperuricemia, back pain, abdominal
pain or discomfort, bronchitis, pain in extremity, anemia, and
elevated liver enzymes.
Adverse reactions reported in ≥2% of patients treated with
ezetimibe (a component of NEXLIZET) and at an incidence greater
than placebo in clinical trials were upper respiratory tract
infection, diarrhea, arthralgia, sinusitis, pain in extremity,
fatigue, and influenza.
In the primary hyperlipidemia trials of NEXLIZET, the most
commonly reported adverse reactions (incidence ≥3% and greater than
placebo) observed with NEXLIZET, but not observed in clinical
trials of bempedoic acid or ezetimibe, were urinary tract
infection, nasopharyngitis, and constipation.
The most common adverse reactions in the cardiovascular outcomes
trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at
an incidence of ≥2% and 0.5% greater than placebo were
hyperuricemia, renal impairment, anemia, elevated liver enzymes,
muscle spasms, gout, and cholelithiasis.
Discontinue NEXLIZET or NEXLETOL when pregnancy is recognized
unless the benefits of therapy outweigh the potential risks to the
fetus. Because of the potential for serious adverse reactions in a
breast-fed infant, breastfeeding is not recommended during
treatment with NEXLIZET or NEXLETOL.
Report pregnancies to Esperion Therapeutics, Inc. Adverse Event
reporting line at 1-833-377-7633.
Please see full Prescribing Information for NEXLIZET and
NEXLETOL.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on X at twitter.com/EsperionInc.
CLEAR Cardiovascular Outcomes TrialCLEAR
Outcomes is part of the CLEAR clinical research program for
NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and
ezetimibe) Tablet. The CLEAR Program seeks to generate important
clinical evidence on the safety and efficacy of bempedoic acid, a
first in a class ATP citrate lyase inhibitor contained in NEXLETOL
and NEXLIZET and its potential role in addressing additional
critical unmet medical needs. More than 60,000 people will have
participated in the program by the time of its completion. The
CLEAR Program includes 5 label-enabling Phase III studies as well
as other key Phase IV studies with the potential to reach more than
70 million people with or at risk for CVD based on elevated
LDL-C.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, current and planned operational expenses, future operations,
commercial products, clinical development, including the timing,
designs and plans for the CLEAR Outcomes study and its results,
plans for potential future product candidates, financial condition
and outlook, including expected cash runway, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the net sales,
profitability, and growth of Esperion’s commercial products,
clinical activities and results, supply chain, commercial
development and launch plans, the outcomes and anticipated benefits
of legal proceedings and settlements, and the risks detailed in
Esperion’s filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Esperion disclaims any obligation
or undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by law.
Esperion Contact Information:Investors: Alina
Veneziainvestorrelations@esperion.com (734) 887-3903
Media: Tiffany Aldrich corporateteam@esperion.com (616)
443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024